You must be 21 years or older to access this website. All products are for research use only.
Are you 21 years of age or older?
By entering, you confirm that you are at least 21 years old and agree to our terms of service.
CJC-1295 / Ipamorelin · Published March 8, 2026 · Updated May 18, 2026 · 8 min read
CJC-1295 No DAC and Ipamorelin show distinct half-lives and stability profiles that shape laboratory handling protocols. This guide covers reconstitution, storage, freeze-thaw considerations, and dosing schedule design relevant to preclinical research with the blend. For research use only, not for human consumption.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
CJC-1295 (No DAC) and Ipamorelin are widely used in laboratory research to study growth hormone-related signaling pathways. For reliable results, understanding the stability, half-life, and handling requirements of these peptides is critical. Proper management ensures reproducible, high-quality data in controlled in vitro experiments.
CJC-1295 is a synthetic 30-amino-acid analog of growth hormone-releasing hormone (GHRH). It is studied in research models as a long-acting GHRH receptor agonist that drives pulsatile growth hormone release from the pituitary.
CJC-1295 no-DAC has a half-life of approximately 30 minutes due to DPP-IV resistance without albumin binding. Ipamorelin has a half-life of about 2 hours. Both are short-acting compared to the DAC form of CJC-1295.
Reconstituted in bacteriostatic water, store refrigerated at 2-8 degrees C. Stability is typically 30 days under these conditions for both peptides individually, with combined formulations following the more conservative timeline of the constituent peptides.
No. CJC-1295 is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.
Key terms used in this article.
Continue exploring research insights and updates.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
Both CJC-1295 (No DAC) and Ipamorelin are supplied as lyophilized powders to preserve integrity during storage and transport. Stability is influenced by factors such as temperature, humidity, and exposure to light. Proper storage conditions are essential to prevent degradation and maintain peptide activity for laboratory use.
The half-life of a peptide influences experimental design and interpretation. CJC-1295 (No DAC) has a shorter half-life than the DAC variant, making it ideal for time-sensitive assays or repeated measurement studies. Ipamorelin also has a relatively short half-life, supporting transient receptor activation and precise temporal control in vitro.
Proper handling of peptides is essential for experimental reliability. Both CJC-1295 (No DAC) and Ipamorelin should be reconstituted using sterile techniques and stored according to laboratory best practices. Consistent documentation ensures reproducibility and allows accurate interpretation of results.
Following recommended stability, half-life, and handling protocols ensures that experimental results are reliable and reproducible. Proper management reduces variability, maintains peptide activity, and supports accurate interpretation of growth hormone-related signaling in vitro.
Research has investigated the impact of storage conditions on peptide integrity, with published findings suggesting that adherence to best practices significantly improves data consistency across experiments.
At Midwest Peptide, our CJC-1295 (No DAC) and Ipamorelin products are supplied with comprehensive quality documentation:
By following stability and handling best practices, researchers can maximize the reliability of CJC-1295 (No DAC) and Ipamorelin studies. This ensures high-quality, reproducible data and deeper insights into growth hormone-related pathways in controlled in vitro experiments.
For research teams investigating growth hormone signaling, proper peptide management provides a structured, reliable framework for safe, accurate, and compliant laboratory studies.
CJC-1295 No DAC (sometimes labeled Modified GRF 1-29 or CJC-1295 without DAC) is a 30-amino-acid analog of the first 29 residues of human growth hormone-releasing hormone (GHRH 1-29) with four substitutions (D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27). The substitutions block the two primary cleavage sites that dipeptidyl peptidase-4 (DPP-4) and trypsin-like proteases recognize in native GHRH. The unmodified parent peptide has a circulating half-life under 7 minutes in primate plasma. The No DAC analog, lacking the maleimidopropionic acid linker that drives albumin conjugation in the DAC version, retains the protease-resistant scaffold but recovers a short, pulse-like signaling window of approximately 30 minutes in vivo.
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) with a molecular weight of 711.85 g/mol and an isoelectric point near 10. It acts as a selective ghrelin receptor (GHSR-1a) agonist and does not appreciably stimulate prolactin or cortisol release at research doses. The compact backbone and C-terminal amidation contribute to a half-life of roughly 2 hours in rodent plasma, longer than most native ghrelin mimetics. Because the molecule lacks aspartate or cysteine residues, the primary degradation pathway under aqueous storage is N-terminal isomerization at the Aib residue rather than oxidation or disulfide scrambling. This matters for buffer selection: phosphate buffered saline at pH 7.4 is generally well-tolerated, while strongly acidic acetate buffers can accelerate Aib racemization over multi-week storage.
A peer-reviewed database review of more than 1,200 therapeutic peptides (Mathur et al., Scientific Reports, 2016) catalogs how primary sequence, terminal modification, and assay matrix together drive observed half-life values. For investigators building dosing schedules for in vitro receptor activation studies, the PEPlife dataset is a useful reference for benchmarking expected stability of structurally similar GHRH and ghrelin-receptor analogs against the published literature.
For laboratory use, both peptides are typically reconstituted in bacteriostatic water containing 0.9 percent benzyl alcohol. The benzyl alcohol both inhibits microbial growth and acts as a mild surfactant that reduces peptide adsorption to glass and polypropylene surfaces. For experiments requiring strictly preservative-free conditions, sterile water for irrigation can be substituted, with the trade-off that the working solution must be used within 24 to 48 hours rather than the 14 to 28 days typical of bacteriostatic preparations.
Concentration matters more than total mass when planning storage. Working solutions below 100 micrograms per milliliter show measurably faster activity loss than concentrated stocks, largely because adsorption losses scale with surface-area-to-volume ratio. A practical workflow is to reconstitute the full lyophilized vial to a single high-concentration stock (typically 2 to 5 milligrams per milliliter), aliquot into single-use volumes in low-binding polypropylene tubes, and flash freeze at minus 80 degrees Celsius. Aliquoting eliminates the need for repeated freeze-thaw cycles, which a recent peer-reviewed analysis (Awotwe-Otoo et al., Journal of Pharmaceutical and Biomedical Analysis, via ScienceDirect, 2021) shows can drive measurable aggregation and potency loss even in well-buffered biotherapeutic systems through a combination of ice-water interface stress and localized pH shifts in the freeze concentrate.
For shorter-term storage at refrigerator temperatures (2 to 8 degrees Celsius), CJC-1295 No DAC retains greater than 95 percent activity for approximately 28 days in bacteriostatic water, while ipamorelin is somewhat more sensitive and is best used within 14 to 21 days under the same conditions. Storage at room temperature should be limited to active assay periods only, ideally under 8 hours.
The pharmacokinetic separation between CJC-1295 No DAC (approximately 30 minute plasma half-life) and ipamorelin (approximately 2 hours) is the core reason the two are studied together. CJC-1295 No DAC provides a short, GHRH-receptor-mediated stimulus that mimics the natural hypothalamic pulse, while ipamorelin provides a sustained ghrelin-receptor stimulus that prolongs the somatotroph response window. In cultured pituitary cell models, this combination produces a measurably larger growth hormone release than either compound alone, an effect first characterized in published studies of GHRH and growth hormone secretagogue receptor co-activation.
When designing repeated-dose receptor desensitization studies, researchers should account for the longer effective signaling tail of ipamorelin. Washout intervals of less than 4 hours between in vitro doses can produce partial receptor downregulation that confounds interpretation of subsequent stimulation curves. For acute single-pulse assays, the short CJC-1295 No DAC half-life makes it a cleaner reference compound than the DAC version, which can produce sustained receptor occupancy for over 144 hours and is therefore unsuitable for time-resolved signaling work.
Documentation discipline is the final piece of reproducibility. Every aliquot used in a published study should be traceable back to a specific lot, reconstitution date, freeze-thaw count, and storage temperature log. This level of provenance is what separates publishable receptor pharmacology from data that fails to reproduce across laboratory groups.
Primary literature and topic hubs from peer-reviewed publishers covering this area of research:
Explore more peer-reviewed research and laboratory guides from our science team:
All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.
Browse our full catalog of research-grade peptides. Every product is third-party tested with a COA included.
Browse ProductsMidwest Peptide supplies research-grade CJC-1295 with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.
The cheapest tirzepatide (GLP-2 TZ) for research is rarely the best value. Here is how to balance price against the analytical specifications that determine research utility.
May 5, 2026
